Apollomics Inc. Warrant

Apollomics, Inc. is a biotechnology company that discovers and develops mono and combination oncology therapies designed to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of development-stage assets, including novel and humanized monoclonal antibodies intended to restore the immune system's ability to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Formerly known as CBT Pharmaceuticals, Inc., the company changed its name to Apollomics, Inc. in January 2019; it was incorporated in 2016 and is based in Foster City, California, with additional locations in Hangzhou and Shanghai, China, and Southbank, Australia.